ERBB2 and breast carcinoma: In light of information on the drug label and new indications approved by NMPA, everolimus and exemestane combination therapy can be used in postmenopausal patients with HR‐positive/HER2‐negative advanced breast cancer after treatment failure with letrozole or anastrozole therapy [16].